Johns Hopkins ABX Guide
Ceftolozane/tazobactam
Ceftolozane/tazobactam is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
- Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
- Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)
Note: FDA indications for age ≥ 18 yrs
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
- Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
- Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)
Note: FDA indications for age ≥ 18 yrs
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])
There's more to see -- the rest of this entry is available only to subscribers.
Last updated: March 21, 2021
Citation
Dzintars, Kathryn. "Ceftolozane/tazobactam." Johns Hopkins ABX Guide, The Johns Hopkins University, 2021. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540650/all/Ceftolozane_tazobactam.
Dzintars K. Ceftolozane/tazobactam. Johns Hopkins ABX Guide. The Johns Hopkins University; 2021. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540650/all/Ceftolozane_tazobactam. Accessed May 16, 2022.
Dzintars, K. (2021). Ceftolozane/tazobactam. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540650/all/Ceftolozane_tazobactam
Dzintars K. Ceftolozane/tazobactam [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2021. [cited 2022 May 16]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540650/all/Ceftolozane_tazobactam.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ceftolozane/tazobactam
ID - 540650
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2021/03/21/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540650/all/Ceftolozane_tazobactam
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
